2004
DOI: 10.1128/iai.72.11.6694-6698.2004
|View full text |Cite
|
Sign up to set email alerts
|

Streptococcus pneumoniae -Induced Inhibition of Rat Ependymal Cilia Is Attenuated by Antipneumolysin Antibody

Abstract: Ciliated ependymal cells line the ventricular surfaces and aqueducts of the brain. In ex vivo experiments, pneumolysin caused rapid inhibition of the ependymal ciliary beat frequency and caused ependymal cell disruption. Wild-type pneumococci and pneumococci deficient in pneumolysin caused ciliary slowing, but penicillin lysis of wild-type, not pneumolysin-deficient, pneumococci increased the extent of ciliary inhibition. This effect was abolished by antipneumolysin antibody. Ependymal ciliary stasis by purifi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
0

Year Published

2006
2006
2023
2023

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(17 citation statements)
references
References 27 publications
0
17
0
Order By: Relevance
“…Additionally, the introduction of a novel class of antimicrobial prophylactic or therapeutic agents would open up possibilities for adjunctive therapy (e.g., coadministration with existing antibiotics), which may result in synergistic effects. The use of existing bactericidal antibiotics can lead to increased release of PFTs from bacteria (as observed, for example, during treatment of S. pneumoniae infection [392]), and adjunctive therapy could also limit the damage caused by the released PFTs (e.g., in line with the S. pneumoniae example, anti-PLY antibodies can limit PLY effects [483], and administration of antibodies that inhibit B. anthracis ALO's cytotoxic properties have a protective effect in B. anthracis-infected mice [484]). …”
Section: Pfts As Targets For Antimicrobial Prophylactics and Therapeumentioning
confidence: 99%
“…Additionally, the introduction of a novel class of antimicrobial prophylactic or therapeutic agents would open up possibilities for adjunctive therapy (e.g., coadministration with existing antibiotics), which may result in synergistic effects. The use of existing bactericidal antibiotics can lead to increased release of PFTs from bacteria (as observed, for example, during treatment of S. pneumoniae infection [392]), and adjunctive therapy could also limit the damage caused by the released PFTs (e.g., in line with the S. pneumoniae example, anti-PLY antibodies can limit PLY effects [483], and administration of antibodies that inhibit B. anthracis ALO's cytotoxic properties have a protective effect in B. anthracis-infected mice [484]). …”
Section: Pfts As Targets For Antimicrobial Prophylactics and Therapeumentioning
confidence: 99%
“…Small animals with primary ciliary dyskinesia (PCD) commonly develop hydrocephalus and hydrocephalus is also occasionally seen in humans with PCD [9,10]. It is known that bacteria and their toxins adversely affect ciliary function [4,5,11] and it has been shown that viral or bacterial infection of the CSF, in animal models, may cause ependymal damage and hydrocephalus [7,8].…”
Section: Introductionmentioning
confidence: 99%
“…Although it is not our intention to detract from the value of β-lactam therapy in CAP, we believe that strategies exist through which the efficacy of β-lactams can be improved. This contention is based on observations that cellwall-targeted antibiotics such as ceftriaxone [72] and penicillin [73] are much less effective inhibitors of pneumolysin synthesis than agents that target protein synthesis [72], and may even increase pneumolysin release due to lysis of bacteria [73]. These apparent limitations of bactericidal, cell-wall-directed antibiotics, albeit derived from experimental systems, are supported by clinical failure rates of 10-15% in CAP in the setting of seemingly appropriate cephalosporin/penicillin monotherapy, and even higher (22-54%) in the intensive care unit setting.…”
Section: Antibiotics and Pneumolysinmentioning
confidence: 98%